The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Smoking Cessation: An Integral Part of Lung Cancer Treatment
Open accessAbstract
Lung cancer is the leading cause of cancer death in the US. About 50% of lung cancer patients are current smokers at the time of diagnosis and up to 83% continue to smoke after diagnosis. A recent study suggests that people who continue to smoke after a diagnosis of early-stage lung cancer almost double their risk of dying. Despite a growing body of evidence that continued smoking by patients after a lung cancer diagnosis is linked with less effective treatment and a poorer prognosis, the belief prevails that treating tobacco dependence is useless. With improved cancer treatments and survival rates, smoking cessation among lung cancer patients has become increasingly important. There is a pressing need to clarify the role of smoking cessation in the care of lung cancer patients. Objective: This paper will report on the benefits of smoking cessation for lung cancer patients and the elements of smoking cessation treatment, with consideration of tailoring to the needs of lung cancer patients. Results: Given the significant benefits of smoking cessation and that tobacco dependence remains a challenge for many lung cancer patients, cancer care providers need to offer full support and intensive treatment with a smoking cessation program that is tailored to lung cancer patients’ specific needs. Conclusion: A tobacco dependence treatment plan for lung cancer patients is provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stages and processes of self-change of smoking: Toward an integrative model of change.
Prochaska, J. O., & DiClemente, C. C. (1983) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.51.3.390 · Cited by 9,098
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“found that smoking significantly lowers both the exposure to irinotecan and treatment-induced neutropenia, indicating a potential risk of treatment failure. Shepherd et al. [”
BackgroundStigma, shame, and blame experienced by patients with lung cancer: qualitative study
Chapple, A., Ziebland, S., & McPherson, A. (2004) · BMJ · doi:10.1136/bmj.38111.639734.7c · Cited by 789 · cited 2×
“[22] Whether they smoked or not, lung cancer patients reported”
BackgroundParsons, A., Daley, A., Begh, R., & Aveyard, P. (2010) · BMJ · doi:10.1136/bmj.b5569 · Cited by 696
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Symptoms in Adults with Lung Cancer
Cooley, M. E. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(99)00150-5 · Cited by 288
Hughes, A. N., O'Brien, M. E. R., Petty, W. J., Chick, J. B., Rankin, E., Woll, P. J., Dunlop, D., Nicolson, M., Boinpally, R., Wolf, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3995 · Cited by 144 · cited 1×
“found that twice the normal dose of erlotinib was required to produce the necessary circulating levels of the drug in smokers compared to never-smokers. In a survival analysis, treatment with erlotinib (p”
BackgroundFoulds, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00955.x · Cited by 136 · cited 1×
“• Varenicline (Chantix). Varenicline is a partial nicotinic agonist; it binds to the nicotinic receptors, thereby preventing nicotine binding. This partial agonist activity induces receptor stimulation and reduces withdrawal symptoms during cessation. Varenicline blocks the dopaminergic stimulation responsible for the…”
Background
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
Wood, D. E., Kazerooni, E. A., Baum, S. L., Eapen, G. A., Ettinger, D. S., Hou, L., Jackman, D. M., Klippenstein, D., Kumar, R., Lackner, R. P., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0020 · Cited by 611
Nicotine-Mediated Cell Proliferation and Tumor Progression in Smoking-Related Cancers
Schaal, C., & Chellappan, S. P. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0541 · Cited by 343
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 259
Continued smoking after a cancer diagnosis: a longitudinal study of intentions and attempts to quit
Paul, C. L., Tzelepis, F., Boyes, A. W., D’Este, C., Sherwood, E., & Girgis, A. (2019) · Journal of Cancer Survivorship · doi:10.1007/s11764-019-00787-5 · Cited by 42
“, up to 83% of patients with lung cancer continue to smoke [12]), but continued smoking is also prevalent among cancers that are not considered by the general public to be directly tobacco related.”
BackgroundPaul, C. L., Warren, G., Vinod, S., Meiser, B., Stone, E., Barker, D., White, K., McLennan, J., Day, F., McCarter, K., et al. (2021) · Implementation Science · doi:10.1186/s13012-021-01092-5 · Cited by 10
Metadata
- Authors
- Cataldo, J. K., Dubey, S., & Prochaska, J. J.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 78
- Issue
- 5-6
- Pages
- 289-301
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2073387905
- Cited by
- 181
- References
- 11
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.